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Abstract
Background: Leishmania parasites cause a diverse spectrum of diseases in humans ranging from
spontaneously healing skin lesions (e.g., L. major) to life-threatening visceral diseases (e.g., L.
infantum). The high conservation in gene content and genome organization between Leishmania
major and Leishmania infantum contrasts their distinct pathophysiologies, suggesting that highly
regulated hierarchical and temporal changes in gene expression may be involved.
Results: We used a multispecies DNA oligonucleotide microarray to compare whole-genome
expression patterns of promastigote (sandfly vector) and amastigote (mammalian macrophages)
developmental stages between L. major and L. infantum. Seven per cent of the total L. infantum
genome and 9.3% of the L. major genome were differentially expressed at the RNA level throughout
development. The main variations were found in genes involved in metabolism, cellular organization
and biogenesis, transport and genes encoding unknown function. Remarkably, this comparative
global interspecies analysis demonstrated that only 10–12% of the differentially expressed genes
were common to L. major and L. infantum. Differentially expressed genes are randomly distributed
across chromosomes further supporting a posttranscriptional control, which is likely to involve a
variety of 3'UTR elements.
Conclusion: This study highlighted substantial differences in gene expression patterns between L.
major  and  L. infantum. These important species-specific differences in stage-regulated gene
expression may contribute to the disease tropism that distinguishes L. major from L. infantum.
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Background
Leishmania are protozoan parasites that cause a wide spec-
trum of clinical manifestations in humans, collectively
referred to as leishmaniasis, ranging from self-resolving
skin lesions (L. major and L. mexicana) to life-threatening
visceral diseases (L. donovani and L. infantum) [1]. Leish-
maniasis is endemic in 88 countries and the World Health
Organization has estimated that more than 12 million
people are currently infected with Leishmania  and 350
million people are at risk of infection in tropical and sub-
tropical regions of the world [1,2]. Leishmania parasites
exist in two major developmental stages. In the alimen-
tary tract of the sandfly vector, the parasites grow as extra-
cellular flagellated promastigotes that are exposed to
neutral pH and fluctuating temperatures averaging 25°C.
Following the sand fly bite, the infective forms (metacy-
clic promastigotes) can be transferred to tissue macro-
phages of the mammalian host where they experience
near-constant temperatures ranging from 35°C to 39°C
and differentiate into aflagellated replicative amastigotes
within the acidic phagolysosomal vacuoles [3]. During
promastigote-to-amastigote differentiation, the parasites
are subjected to drastic environmental changes, including
a sharp rise in temperature, a drop in extracellular pH, an
increased exposure to oxygen and nitrogen-reactive spe-
cies, an intense extracellular proteolytic activity, and nutri-
tional starvation. Several of these environmental signals
trigger Leishmania differentiation [4-6] by activating many
regulatory mechanisms affecting gene expression that
result in important morphological and biochemical
changes [7-10]. To date, several amastigote-specific [11-
15] and promastigote-specific [16-18] genes have been
identified in Leishmania, however, the molecular mecha-
nisms governing developmental gene regulation in this
organism warrant additional investigations.
Leishmania and the related Trypanosoma  species possess
unusual mechanisms of gene expression. The recent com-
pletion of the Leishmania spp. genomes indicates that pro-
tein-coding genes are organized as large polycistronic
units [19,20]. Transcription has been postulated to initi-
ate at strand switch regions on each chromosome [21] in
the absence of defined RNA pol II promoters and typical
general transcription factors. The maturation of individ-
ual mRNAs from polycistronic pre-mRNAs requires post-
transcriptional control, which involves two coupled co-
transcriptional RNA-processing reactions. These include
trans-splicing where a capped RNA of ~39-nucleotides, the
spliced leader RNA, is added to the 5'-terminus of all
known protein-encoding RNAs, and 3'-end cleavage and
polyadenylation (reviewed in [22]). Developmental gene
regulation in Leishmania is determined posttranscription-
ally mainly by sequences located in the 3'-untranslated
regions (3'UTR). Several distinct 3'UTR elements have
been identified among stage-specific transcripts to regu-
late mRNA stability/degradation and mRNA translation
(reviewed in [22,23]).
The recent completion of the L. major and L. infantum
genomic sequences [24] allowed studies of global gene
expression throughout developmental life stages of these
parasites. Global gene expression profiling using Leishma-
nia microarrays with genome coverage between 22% and
97.5% highlighted that 2–9% of all genes analyzed were
developmentally regulated [25-29]. The current study
extends these microarray data by providing a detailed
analysis of whole-genome stage- and species-specific gene
expression profiles within L. major and L. infantum using
a DNA oligonucleotide microarray representing the entire
genomes of these two species. None of the previous DNA
microarray studies has compared global gene expression
profiling of promastigote (extracellular) versus amastigote
(intracellular) forms of L. infantum, the causative agent of
visceral leishmaniasis, the most severe form of the disease.
Moreover, no studies to date have compared global
changes in mRNA abundance during development
between Leishmania species associated with different dis-
ease tropism (e.g. cutaneous vs. visceral leishmaniasis).
Table 1: Patterns of global differential gene expression in Leishmania infantum and Leishmania majora.
L. infantum L. major
Fold increase promastigotes amastigotes promastigotes amastigotes
1.7–3.0 260 217 413 233
3.1–6.0 14 52 63 35
6.1–9.0 0 19 4 15
9.1–12.0 0 9 1 7
> 12.1 0 12 0 11
Total 274 309 481 301
% of modulated genes 3.3 3.8 5.7 3.6
a All genes presented here (total 1365) showed a fold increase in mRNA accumulation more than 1.7 and a p value < 0.05.BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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The current comparative analyses revealed important dif-
ferences in stage-regulated gene expression patterns
between L. major and L. infantum. These species-specific
differences may partly explain the distinct clinical pathol-
ogies, despite highly conserved genomes.
Results
Comparison of global gene expression profiles between 
promastigote and amastigote developmental stages of 
Leishmania spp
To investigate global mRNA expression profiles of L.
infantum and L. major promastigote and amastigote devel-
opmental life stages, we designed a high-density multispe-
cies 70-mer oligonucleotide genome microarray
representing the entire genomes of L. major and L. infan-
tum that share over 99% of their genes and contain spe-
cies-specific genes. This allows a comparative analysis
under the same conditions. Through a rigorous statistical
approach, data from several independent L. infantum and
L. major DNA microarray experiments were compiled and
compared here. After subtracting the background, the dif-
ference of 1.7-fold in the signal intensity between the
experimental conditions used (promastigote vs. amastig-
ote RNA) for a given gene was chosen as the cut-off given
that the p value confidence was more than 95% under
those conditions. The whole-genome expression patterns
of L. infantum (Figure 1A) and L. major (Fig. 1B) develop-
mental stages are shown in the scatter plots of normalized
data. The scatter plots compared each gene according to
the normalized log2 ratio of the Alexa 647/Alexa 555 sig-
nal intensities (amastigotes/promastigotes) and to the sig-
nal mean intensity of each spot. More than 86% of the
spots yielded hybridization intensities of two-fold over
local background. Non-modulated genes, considered as
constitutively expressed, had ratios between 0.6 and 1.7
(log2 = ± 0.75). Remarkably, most Leishmania  spots
yielded expression ratios close to 1 (log2 = 0), with only a
few hundred genes showing modulation of greater than
1.7-fold between developmental stages in both species
(Figure 1 and Table 1). The vast majority of genes (91–
93%) in both Leishmania species were not significantly
modulated (less than 1.7-fold modulation at the level of
mRNA expression) throughout the two life cycle stages
studied.
Comparison of global gene expression profiles of 
Leishmania infantum developmental stages
To date, no studies on the global stage-specific gene
expression of a visceralizing Leishmania species have been
reported. We therefore undertook a microarray-based
approach to determine differential gene expression pat-
terns of the two major L. infantum life cycle stages: (i) non-
infective replicating extracellular procyclic promastigotes,
and (ii) intracellular amastigotes isolated from THP-1-
infected human monocytes in vitro following 4 days post-
infection. Hybridizations were carried out using RNA
from six experimental biological replicates. After normal-
ization and data processing in order to assess differential
gene expression, the data were first filtered by FDR-cor-
rected p-value (p < 0.05) and then according to the modu-
lation of each probe (see Methods). This analysis led to
583 genes (7.3% of the total L. infantum genome) show-
ing > 1.7-fold change in mRNA abundance between the
promastigote and amastigote life stages (Table 1). Analy-
sis of the stage-modulated genes according to their gene
ontology (GO) showed that they belong to several catego-
ries, including various biological processes (see Addi-
tional files 1 and 2 and Figure 2A–B).
Two hundred and seventy four genes representing 3.3% of
the L. infantum genome were preferentially expressed in
procyclic promastigotes (listed in Additional file 1). Fold-
increase in mRNA abundance was modest (1.7- to 3-fold)
for 95% of the overexpressed transcripts (Table 1). This
group included the well-documented promastigote-regu-
lated genes PFR1D and PFR2C [18], several dyneins and
Whole-genome expression profiling of amastigote vs. pro- mastigote upregulated transcripts in Leishmania spp Figure 1
Whole-genome expression profiling of amastigote vs. 
promastigote upregulated transcripts in Leishmania 
spp. Scatter plots showing the distribution of signal intensi-
ties generated by the DNA microarray experiments employ-
ing total RNA of L. infantum (A) and L. major (B) extracted 
from promastigote (Pro) and amastigote (Ama) developmen-
tal life stages. The horizontal axis displays the normalized 
mean signal intensity for each gene (([Pro]+ [Ama]/2) and the 
vertical axis shows the normalized ratio of amastigote versus 
promastigote gene expression ([Ama]/[Pro]). External line 
represents a 1.7-fold change. Genes significantly upregulated 
in the amastigote stage are above the line at 1.7 and genes 
upregulated in the promastigote stage are below the line at 
0.6. The data presented here are the average of six independ-
ent biological replicates for L. infantum and four independent 
biological replicates for L. major.BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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kinesins that are important for flagellar movement, cyto-
kinesis, and motility [30,31], histones [32,33], kineto-
plast DNA-associated proteins, the U-rich RNA-binding
proteins UPB1 and UBP2 [34] and a member of the
Pumilio family of translation repressors [35], calpain
cysteine peptidases and several proteasome subunits (see
Additional file 1). Half of the promastigote-upregulated
genes (49%) encoded hypothetical proteins with no sim-
ilarity to other known proteins in the databases.
Three hundred and nine genes, representing 3.8% of the
total L. infantum protein-coding sequences (Table 1) were
found upregulated in intracellular amastigotes compared
to extracellular promastigotes (listed in Additional file 2).
Transcripts modulated specifically in amastigotes showed
generally a higher accumulation than promastigote-
upregulated transcripts, with 31% of the transcripts dem-
onstrating more than 3-fold increase in expression levels
(average of 9.5-fold) (Table 1). Several well-documented
gene families, including the amastins [15], members of
the glycosylation phosphoglycan beta 1,3 galactosyltrans-
ferase gene family (SCG: Side Chain Galactose) [36] and
SHERP1, a small hydrophilic protein localizing to the
endoplasmic reticulum and outer mitochondrial mem-
brane [29,37] were upregulated in L. infantum amastig-
otes. Other representative examples included the myo-
inositol-1-phosphate synthase, a mRNA capping methyl-
transferase involved in cap4 methylation of the spliced-
leader RNA [38], aminopeptidases and the hs1vu complex
proteolytic subunit and several ABC, amino acid and
mitochondrial transporters (see Additional file 2).
Approximately 74% of the amastigote-upregulated genes
encoded hypothetical or unclassified proteins for which
no putative biological function has been assigned.
Distribution of Leishmania infantum and Leishmania major differentially expressed genes according to Gene Ontology (GO) func- tion categories Figure 2
Distribution of Leishmania infantum and Leishmania major differentially expressed genes according to Gene 
Ontology (GO) function categories. GO categories for L. infantum promastigotes (A), L. infantum amastigotes (B), L. major 
promastigotes (C) and L. major amastigotes (D). The majority of genes encode unknown biological functions. Unclassified pro-
teins include the hypothetical proteins (proteins with unknown function and not tested experimentally) and proteins with no 
GO category (unclassified) that have been experimentally characterized (e.g. amastins).BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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Comparison of global gene expression profiles of different 
developmental stages within Leishmania major
In order to compare mRNA expression profiles between L.
infantum  and  L. major developmental life stages, we
undertook also DNA microarray experiments with L.
major. In this study, we used the L. major LV39 MRHO/SU/
59/P strain instead of the L. major Friedlin genome strain
(MHOM/IL/81/Friedlin) because in our hands L. major
LV39 was more infectious in BALB/c mice. Hybridizations
were performed using RNA from four experimental bio-
logical replicates. Using the same statistical analysis
applied for L. infantum, we identified 782 differentially
expressed transcripts in L. major (9.3% of the total L. major
genes) from which 481 were preferentially expressed in
procyclic promastigotes (5.7%) and 301 were differen-
tially expressed in lesion-derived amastigotes (3.6%)
(Table 1). Recent microarray analyses reported that 1.5%
of the L. major genes were differentially expressed in pro-
mastigotes and 1.4% in lesion-derived amastigotes [28].
The observed differences between the two studies may be
attributed to the different L. major strains used or to tech-
nical issues regarding RNA preparations from mice lesions
and/or to differences in the oligonucleotide genome
microarray design and manipulation. The 782 identified
differentially expressed genes were grouped according to
GO functional categories (see Additional files 3 and 4 and
Figure 2C–D). The vast majority of the transcripts
enriched in L. major promastigotes (86%) showed a mod-
est accumulation not exceeding 3-fold. Similarly to L.
infantum, several L. major amastigote-upregulated tran-
scripts showed in average a higher differential accumula-
tion than the promastigote-upregulated transcripts (Table
1). Representative genes among those specifically upregu-
lated in L. major promastigotes encode sugar kinases and
beta-fructofuranosidases involved in carbohydrate metab-
olism, fatty acid elongases involved in lipid metabolism,
proteins participating in nucleoside-nucleotide metabo-
lism, amino acid, glucose and pteridine transport, elec-
tron transport, proteolysis (e.g. members of the calpain-
like cysteine peptidase and peptidyl dipeptidase families),
signaling (e.g. MAP and serine/threonine kinases, a PP1
Ser/Thr phosphatase, calmodulins, receptor-type ade-
nylate cyclase a and b) and a large number of microtu-
bule-associated proteins (see Additional file 3). This
group also included several well-documented differen-
tially expressed genes in promastigotes such as histones
[26,39], the glucose transporter GT2 [14], the paraflagel-
lar rod protein PFR1D and PFR2C [18], the leish-
manolysin GP63 (also called MSP) [40,41], and the
surface antigen protein 2 gene family (also known as
GP46) [16,42]. More than 47% of the promastigote-
upregulated transcripts encoded hypothetical proteins of
unknown function (see Additional file 3). Among the L.
major amastigote-upregulated genes are included several
well-documented gene families such as amastins [15],
HASPA1,2 [37], SCG5 and SCG7 which are members of
the phosphoglycan beta 1,3 galactosyltransferase gene
family [36], and others such as RNA-binding proteins,
cathepsin L-like proteins, protein kinases, tryparedoxins, a
family of novel antioxidant proteins, several amino acid
and pteridine transporters and a large number (51%) of
hypothetical proteins (see Additional file 4).
Comparison of global stage-regulated gene expression 
between L. infantum and L. major
One of the goals of this study was to compare global gene
expression within the same life cycle stages of the L. major
and L. infantum species, the causative agents of cutaneous
and visceral leishmaniasis, respectively. Sequence com-
parison between the L. major and L. infantum genomes
revealed marked conservation of synteny [20]. Therefore,
much of the species-specific adaptive strategies to differ-
ent target tissues and distinct disease pathogenesis should
depend on the non-syntenic part of their respective
genomes and/or on highly regulated hierarchical and tem-
poral changes in gene expression. To monitor global gene
expression of L. infantum and L. major, we used a multi-
species high-density oligonucleotide microarray. It has
recently been reported that using a multispecies microar-
ray to study related species provided superior inter-species
comparison than using several single species-specific
microarrays [43]. Our comparative microarray analyses
showed that out of the 755 genes differentially expressed
in L. infantum and L. major promastigote forms (Figure 3)
only 91 (12.05%) were in common between the two spe-
cies. Similarly, only 64 (10.5%) of the 610 amastigote-
upregulated genes were common to both species. These
results are displayed in the form of Venn diagrams (Figure
3) and the detailed list of the commonly upregulated
genes between L. infantum and L. major for a given devel-
opmental life stage is provided in Table 2. This list
included, among others, the amastigote-specific amastin
surface proteins, the paraflagellar rod components upreg-
ulated in promastigotes, dyneins, members of the phos-
phoglycan beta 1,3 galactosyltransferase, calpain-like
cysteine peptidases, calmodulins and a large number of
hypothetical proteins.
One hundred and nineteen genes were differentially
expressed in L. infantum but were not modulated in L.
major (Table 3). More than 50% of these genes encoded
hypothetical proteins. For example, the LinJ29_V3.0930
gene was overexpressed 47-fold in L. infantum amastigotes
but mRNA expression of its L. major orthologue remained
unchanged. Other examples of genes upregulated in L.
infantum amastigotes but not developmentally regulated
in L. major included the aminopeptidase LinJ33_V3.2700
and metallopeptidases LinJ16_V3.0850 and
LinJ34_V3.1130, the ABC transporters LinJ29_V3.0640
and LinJ11_V3.0040, the Rab GTPase activator proteinBMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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Table 2: Differentially expressed genes common to Leishmania infantum and Leishmania major.
GO annotation (molecular function) Accession number 
(GeneDB) L. infantum
Fold 
increase
Accession number 
(GeneDB L. major
Fold 
increase
Metabolic process
3-ketoacyl-coa thiolase LinJ23_V3.0860 2,1 a LmjF23.0690 3,3 a
hydrolase, alpha/beta fold family LinJ17_V3.1110 1,7 a LmjF17.1010 1,8 a
vacuolar ATP synthase subunit B LinJ28_V3.2610 1,8 a LmjF28.2430 1,7 a
succinyl-coA:3-ketoacid-coenzyme A transferase b LinJ33_V3.2470 1,8 c LmjF33.2340 2,1 a
hydrolase, alpha/beta fold family LinJ17_V3.1110 1,7 c LmjF17.1010 1,8 c
Carbohydrate metabolic process
acetyl-CoA synthetase LinJ23_V3.0880 2,0 a LmjF23.0710 4,5 a
aldose 1-epimerase LinJ35_V3.1000 1,8 a LmjF35.0980 2,4 a
enolase LinJ14_V3.1240 2,3 a LmjF14.1160 2,4 a
myo-inositol-1-phosphate synthetase LinJ14_V3.1450 2,4 c LmjF14.1360 4,7 c
Lipid metabolic process
3-oxo-5-alpha-steroid 4-dehydrogenase LinJ25_V3.1850 1,7 a LmjF25.1770 3,0 a
fatty acid elongase LinJ14_V3.0700 2,0 a LmjF14.0670 3,2 a
lathosterol oxidase LinJ23_V3.1560 1,9 a LmjF23.1300 3,6 a
phosphoglycan beta 1,3 galactosyltransferase LinJ02_V3.0140 1,8 a LmjF02.0160 3,8 a
phosphoglycan beta 1,3 galactosyltransferase d 22,0 c 2,4-11,8 c
hypothetical LinJ13_V3.0200 2,7 c LmjF13.0200 3,8 c
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
adenylosuccinate synthetase LinJ13_V3.1090 1,8 a LmjF13.1190 2,0 a
LinJ25_V3.1210
LinJ25_V3.2580 LmjF25.1170,
ATPase beta subunit LinJ25_V3.2590 2,1 a LmjF25.1180 1,9 a
DNA metabolic process
3'-nucleotidase/nuclease LinJ12_V3.0350 2,0 a LmjF12.0400 3,9 a
3'-nucleotidase/nuclease precursor LinJ31_V3.2380 1,7 a LmjF31.2310 4,6 a
histone 1 LinJ33_V3.3390 2,6 a LmjF33.3240 1,9 a
3'-nucleotidase/nuclease LinJ31_V3.2370 2,0 c LmjF31.2300 1,7 c
double-strand-break repair protein rad21 LinJ05_V3.1090 3,0 c LmjF05.1090 1,9 c
RNA metabolic process
exosome complex exonuclease RRP45 LinJ22_V3.1430 3,1 c LmjF22.1580 1,8 c
RNA-binding protein 5 LinJ09_V3.0080 3,4 c LmjF09.0060 1,7 c
Amino acid and derivative metabolic process
glutamate dehydrogenase LinJ15_V3.1070 1,8 a LmjF15.1010 1,8 a
Protein metabolic process
HSP 70 LinJ32_V3.2050 2,0 a LmjF32.1940 1,9 a
Proteolysis
LinJ14_V3.0910,
calpain-like cysteine peptidase LinJ14_V3.0920 1,7 a LmjF14.0850 4,5 aBMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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calpain-like cysteine peptidase LinJ20_V3.1320 2,0 a LmjF20.1280 2,1 a
calpain-like cysteine peptidase LinJ20_V3.1350 1,7 a LmjF20.1310 2,9 a
calpain-like cysteine peptidase LinJ27_V3.2490 1,8 a LmjF27.0510 2,8 a
calpain-like cysteine peptidase LinJ32_V3.1020 1,8 a LmjF32.0970 1,9 a
LmjF01.0830,
LmjF02.0740,
peptidyl-dipeptidase LinJ02_V3.0710 1,7 a LmjF27.2660 2,5 a
puromycin-sensitive aminopeptidase-like LinJ12_V3.0830 2,1 c LmjF12.1250 1,8 c
Protein modification process
protein kinase A catalytic subunit LinJ18_V3.1090 1,9 a LmjF18.1080 3,2 a
protein kinase A regulatory subunit LinJ13_V3.0160 2,5 a LmjF13.0160 2,1 a
protein kinase LinJ30_V3.1780 2,5 c LmjF30.1780 1,7 c
Electron transport
trypanothione synthetase LinJ23_V3.0500 1,7 c LmjF23.0460 1,8 c
Cellular component organization and biogenesis
dynein heavy chain LinJ13_V3.1390 1,7 a LmjF13.1650 2,1 a
dynein heavy chain LinJ26_V3.1000 1,9 a LmjF26.1020 1,7 a
dynein heavy chain LinJ28_V3.0650 1,8 a LmjF28.0610 2,0 a
dynein heavy chain (pseudogene) LinJ27_V3.2460 2,1 a LmjF27.2590 2,0 a
dynein light chain LinJ24_V3.1050 2,0 a LmjF24.1030 2,0 a
dynein-associated roadblock LinJ35_V3.1740 1,8 a LmjF35.1750 2,1 a
OSM3-like kinesin LinJ17_V3.0890 1,7 a LmjF17.0800 2,0 a
Cell motility
LmjF39.1750,
LinJ29_V3.1880, LmjF29.1760
PFR 1D LinJ29_V3.1890 3,9 a LmjF29.1770 4,5 a
LinJ16_V3.1510, LmjF16.1425,
PFR 2C LinJ16_V3.1520 3,7 a LmjF16.1430 5,3 a
paraflagellar rod component LinJ09_V3.1390 1,9 a LmjF09.1320 2,8 a
Cell communication
LmjF09.0910,
LinJ09_V3.0970, LmjF09.0920
calmodulin LinJ09_V3.0980 2,0 a LmjF09.0930 2,8 a
calmodulin LinJ13_V3.1060 1,8 a LmjF13.1160 1,8 a
receptor-type adenylate cyclase a LinJ17_V3.0120 1,7 a LmjF17.0200 1,8 a
LmjF17.0230,
LinJ17_V3.0140, LmjF17.0235
receptor-type adenylate cyclase b LinJ17_V3.0160 1,8 a LmjF17.0237 2,6 a
Transport
amino acid transporter aATP11 b LinJ31_V3.0370 2,4 c LmjF31.0350 4,7 a
phosphate-repressible phosphate permease LinJ03_V3.0480 1,7 c LmjF03.0500 2,0 c
Unclassified
oxidoreductase LinJ36_V3.4380 1,7 a LmjF36.4170 1,7 a
leucine rich repeat protein LinJ32_V3.3200 1,7 a LmjF32.3010 2,2 a
leucine rich repeat protein LinJ10_V3.0160 2,1 a LmjF10.0180 2,3 a
protein tyrosine phosphatase LinJ05_V3.0280 1,8 a LmjF05.0280 2,6 a
Table 2: Differentially expressed genes common to Leishmania infantum and Leishmania major. (Continued)BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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hypothetical LinJ01_V3.0640 2,4 a LmjF01.0620 2,3 a
hypothetical LinJ02_V3.0520 3,9 a LmjF02.0550 5,0 a
hypothetical LinJ07_V3.0040 2,0 a LmjF07.0030 1,8 a
hypothetical LinJ07_V3.0470 1,8 a LmjF07.0310 2,7 a
hypothetical LinJ09_V3.1620 2,1 a LmjF09.1530 1,8 a
hypothetical LinJ10_V3.1370 1,9 a LmjF10.1230 1,9 a
hypothetical LinJ11_V3.0620 2,0 a LmjF11.0610 2,1 a
hypothetical LinJ11_V3.1040 2,1 a LmjF11.1040 2,0 a
hypothetical LinJ17_V3.0970 2,0 a LmjF17.0870 3,6 a
hypothetical LinJ18_V3.1640 3,5 a LmjF18.1640 6,6 a
hypothetical LinJ19_V3.0520 4,5 a LmjF19.0520 5,9 a
hypothetical LinJ20_V3.0760 1,7 a LmjF20.0700 1,8 a
hypothetical LinJ21_V3.0440 1,8 a LmjF21.0380 2,5 a
hypothetical LinJ23_V3.1190 2,0 a LmjF23.1020 4,6 a
hypothetical LinJ24_V3.1630 4,1 a LmjF24.1560 4,1 a
hypothetical LinJ24_V3.2200 2,4 a LmjF24.2110 1,8 a
hypothetical LinJ26_V3.2400 2,1 a Lm jF26.2380 3,0 a
hypothetical LinJ27_V3.0720 1,9 a LmjF27.0870 1,7 a
hypothetical LinJ28_V3.1150 2,1 a LmjF28.1060 2,9 a
hypothetical LinJ29_V3.0360 1,7 a Lm jF29.0350 1,9 a
hypothetical LinJ29_V3.1090 2,4 a Lm jF29.1000 3,0 a
hypothetical LinJ29_V3.1190 2,0 a Lm jF29.1100 1,8 a
hypothetical LinJ29_V3.1260 2,5 a Lm jF29.1170 3,2 a
hypothetical LinJ29_V3.2940 2,5 a Lm jF29.2830 3,7 a
hypothetical LinJ30_V3.2870 4,4 a Lm jF30.2850 8,5 a
hypothetical LinJ31_V3.1220 2,7 a LmjF31.1200 2,0 a
hypothetical LinJ32_V3.0360 1,7 a Lm jF32.0350 2,0 a
hypothetical LinJ32_V3.0370 2,2 a Lm jF32.0360 2,2 a
hypothetical LinJ32_V3.1840 2,2 a Lm jF32.1760 3,0 a
hypothetical LinJ32_V3.2020 2,8 a Lm jF32.1910 2,4 a
hypothetical LinJ33_V3.0660 3,7 a Lm jF33.0610 5,4 a
hypothetical LinJ34_V3.1620 2,0 a Lm jF34.1520 4,0 a
hypothetical LinJ34_V3.2590 1,7 a LmjF34.2760 1,8 a
hypothetical LinJ34_V3.4230 1,9 a Lm jF34.4600 3,0 a
hypothetical LinJ35_V3.5310 2,4 a Lm jF35.5340 4,0 a
hypothetical LinJ36_V3.0800 2,4 a LmjF36.0740 1,8 a
hypothetical LinJ36_V3.3000 1,8 a Lm jF36.2850 2,0 a
hypothetical LinJ36_V3.3780 1,8 a Lm jF36.3620 6,7 a
hypothetical LinJ36_V3.4440 4,1 a Lm jF36.4230 5,7 a
hypothetical LinJ36_V3.5010 2,7 a Lm jF36.4780 3,2 a
hypothetical LinJ36_V3.5140 2,3 a LmjF36.4910 1,9 a
hypothetical LinJ36_V3.5210 1,8 a LmjF36.4980 2,5 a
hypothetical LinJ35_V3.3780 1,8 c LmjF35.3730 1,7 a
LmjF 23.1050,
LinJ23_V3.1210, LmjF 23.1080,
SHERP b LinJ23_V3.1230 2,5 c LmjF23.1086 1,7 a
Amastins e 1.9–6.8 c 1.9–25.4 c
LmjF 05.1230,
LmjF19.1650
GIPL galf transferase LinJ32_V3.4140 2,8 c LmjF32.3990 2,0 c
hypothetical LinJ01_V3.0650 1,7 c LmjF01.0630 2,5 c
hypothetical LinJ06_V3.1030 2,1 c LmjF06.0995 1,8 c
hypothetical LinJ08_V3.0650 2,0 c Lm jF08.0640 4,8 c
hypothetical LinJ10_V3.1130 2,7 c LmjF10.1050 1,8 c
hypothetical LinJ12_V3.0440 1,9 c Lm jF12.0480 5,1 c
hypothetical LinJ16_V3.0100 1,9 c Lm jF16.0090 2,5 c
hypothetical LinJ24_V3.2320 2,7 c LmjF24.2230 1,7 c
hypothetical LinJ25_V3.2870 2,3 c LmjF35.2820 1,8 c
hypothetical LinJ26_V3.1440 1,8 c Lm jF26.1460 2,0 c
hypothetical LinJ27_V3.0770 20,8 c Lm jF27.0910 1,9 c
hypothetical LinJ27_V3.2320 2,5 c LmjF27.2370 1,8 c
hypothetical LinJ30_V3.0820 2,0 c LmjF30.0770 1,8 c
hypothetical LinJ30_V3.1000 7,1 c LmjF30.0940 2,7 c
Table 2: Differentially expressed genes common to Leishmania infantum and Leishmania major. (Continued)BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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hypothetical LinJ30_V3.2340 1,7 c Lm jF30.2330 2,4 c
hypothetical LinJ31_V3.1190 2,1 c Lm jF31.1170 2,7 c
hypothetical LinJ 31_V 3.2140 1,9 c LmjF 31.2090 2,0 c
hypothetical LinJ 32_V3.3600 1,9 c LmjF 32.3400 2,3 c
hypothetical LinJ 33_V3.1720 4,2 c Lm jF 33.1620 4,5 c
hypothetical LinJ 35_V3.5130 1,7 c Lm jF 35.5160 1,8 c
a Genes differentially expressed in promastigotes.
b Genes differentially expressed but not in the same life stage.
c Genes differentially expressed in amastigotes.
d The majority of the phosphoglycan 1,3 galactosyltransferase gene family members are differentially expressed in amastigotes. These genes are 
listed in Additional files 2 and 4.
e The majority of the amastin gene family members are differentially expressed in amastigotes. These genes are listed in Additional files 2 and 4.
Table 2: Differentially expressed genes common to Leishmania infantum and Leishmania major. (Continued)
LinJ29_V3.1670, the chaperone DNAJ LinJ21_V3.0550,
the kinesin LinJ25_V3.2050, the mRNA capping methyl-
transferase LinJ36_V3.0130 and the nuclear cap binding
protein LinJ30_V3.0560 (Table 3). Alternatively, 131
genes were stage-regulated in L. major but constitutively
expressed in L. infantum (Table 4). Most of these L. major
species-regulated genes were predominantly expressed in
promastigotes. These included genes involved in carbohy-
drate metabolism like the three beta-fructofuranosidases
in the L. major genome, 6-phospho-1-fructokinase
LmjF29.2510 and hexokinase LmjF21.0250, genes partic-
ipating in proteolysis such as the calpain-like cysteine
peptidases LmjF20.1190 and LmjF27.0510 and carbox-
ypeptidases LmjF13.0090 and LmjF33.2540, genes
involved in electron transport such as the lactate dehydro-
genase LmjF29.0280, the amino acid permease
LmjF27.0680 and the transmembrane amino acid trans-
porter LmjF07.1160 (9.7-fold of regulation), the glucose
transporters lmgt2 LmjF36.6280/LmjF36.6290 and the
surface antigens prostaglandin f2-alpha synthase and
membrane-bound acid phosphatase 2 (Table 4). Previous
studies have reported that the membrane-bound acid
phosphatase 2 is a marker of virulence of L. donovani pro-
mastigotes [44] and that in L. mexicana this gene was not
required for amastigote survival [45].
Confirmation of gene expression patterns by quantitative 
real-time PCR
Quantitative real-time PCR (qRT-PCR) was used to vali-
date the microarray results. Changes in expression levels
of 80 selected L. infantum and/or L. major mRNAs in either
promastigotes or intracellular amastigotes as determined
by the microarray experiments were confirmed by qRT-
PCR. Genes for qRT-PCR were randomly selected based
on different criteria, which included high vs. lower levels
of expression, constitutive vs. stage-regulated gene expres-
sion, different GO categories or genes encoding unclassi-
fied proteins, single copy genes and genes belonging to
larger gene families. mRNA expression levels determined
by qRT-PCR were normalized to three L. infantum and L.
major  constitutively expressed mRNAs (see Methods).
Estimated expression patterns by qRT-PCR were com-
pared to those by DNA microarrays. Results obtained by
qRT-PCR were consistent with the microarray data in
more than 97% of the cases (Table 5). In few cases
Comparison of differential mRNA expression between Leish- mania major and Leishmania infantum Figure 3
Comparison of differential mRNA expression 
between Leishmania major and Leishmania infantum. 
Venn diagram comparing L. infantum and L. major genes signif-
icantly upregulated (> 1.7-fold, p < 0.05) in either log-phase 
promastigotes or intramacrophage amastigotes. The inter-
section of the Venn diagrams shows the number of genes 
that were common to both species. These common genes 
are listed in Table 2. The numbers within separate circles 
correspond to differentially expressed genes that are unique 
to each species. Species comparison was performed only on 
probes that had less than two mismatches when hybridized 
to either Leishmania species. Thus, ~7000 probes could be 
directly compared between the two organisms.BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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Table 3: Genes differentially expressed in Leishmania infantum but constitutively expressed in Leishmania major.
GO annotation (molecular 
function)
Accession number (GeneDB) Fold increase Accession number (GeneDB) Fold increase a
L. infantum L. major
Metabolic process
glycerolphosphate mutase LinJ33_V3.2220 2,2 b LmjF33.2100 1,4
iron superoxide dismutase LinJ32_V3.1920 1,9 b LmjF32.1839 1,2
proteasome alpha 7 subunit LinJ27_V3.0190 1,9 b LmjF27.0190 1,3
pyruvate phosphate dikinase LinJ11_V3.1000 1,8 b LmjF11.1000 1,3
nuclear receptor binding factor-like 
protein
LinJ05_V3.0520 2,1 c LmjF05.0520 1,3
quinone oxidoreductase LinJ03_V3.0550 11,7 c LmjF03.0570 1,0
quinonoid dihydropteridine reductase LinJ34_V3.4270 20,2 c LmjF34.4330 1,0
Response to oxidative stress
ascorbate-dependent peroxidase LinJ34_V3.0070 3,0 b LmjF34.0070 1,6
Carbohydrate metabolic process
6-phosphogluconate dehydrogenase, 
decarboxylating
LinJ35_V3.3390 2,0 b LmjF35.3340 1,0
pyruvate kinase LinJ35_V3.5450 1,9 b LmjF35.0030 1,4
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
thymidine kinase LinJ21_V3.1450 1,7 b LmjF21.1210 1,3
DNA-directed RNA polymerase, 
alpha subunit
LinJ19_V3.0660 1,9 c LmjF19.0660 1,0
nuclear cap binding protein LinJ30_V3.0560 4,1 c LmjF30.0540 1,1
vacuolar ATP synthase subunit LinJ12_V3.0480 1,7 c LmjF12.0520 1,0
DNA metabolic process
kinetoplast DNA-associated protein LinJ36_V3.6180 1,8 b LmjF36.5920 1,1
RNA metabolic process
RNA binding protein LinJ04_V3.1190 2,2 b LmjF04.1170 1,0
RNA binding protein UBP1 LinJ25_V3.0500 2,1 b LmjF25.0490 1,1
RNA binding protein UBP2 LinJ25_V3.0510 2,1 b LmjF25.0500 1,1
mRNA capping methyltransferase LinJ36_V3.0130 7,3 c LmjF36.0120 1,1
pseudouridylate synthase-like LinJ01_V3.0280 1,9 c LmjF01.0280 1,1
RNA-binding protein LinJ17_V3.0610 1,7 c LmjF17.0550 1,3
RNase PH-like exosome associated 
protein 1
LinJ20_V3.1400 2,0 c LmjF20.1360 1,1
Amino acid and derivative metabolic process
glycine dehydrogenase LinJ26_V3.0040 8,1 c LmjF26.0030 1,4
Protein metabolic process
Proteolysis
mitochondrial processing peptidase, 
beta subunit
LinJ35_V3.1390 2,1 b LmjF35.1380 1,0
aminopeptidase LinJ19_V3.0150 1,7 c LmjF19.0160 1,2BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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aminopeptidase LinJ33_V3.2700 4,7 c LmjF33.2570 1,3
mitochondrial ATP-dependent zinc 
metallopeptidase
LinJ34_V3.1130 3,6 c LmjF34.1060 1,1
Protein folding
chaperone protein DNAJ LinJ18_V3.1470 1,8 c LmjF18.1490 1,1
DNAJ protein LinJ21_V3.0550 4,5 c LmjF21.0490 1,0
Protein modification process
protein kinase LinJ27_V3.0100 4,6 c LmjF27.0100 1,0
Electron transport
oxidoreductase-like protein LinJ19_V3.1490 1,7 b LmjF19.1450 1,0
trypanothione reductase LinJ05_V3.0350 1,7 b LmjF05.0350 1,1
Transport
mitochondrial carrier protein LinJ35_V3.3380 1,8 b LmjF35.3330 1,5
LinJ28_V3.2050,
zinc transporter LinJ28_V3.2060 2,5 b LmjF28.1930 1,2
ABC transporter LinJ29_V3.0640 4,8 c LmjF29.0620 1,6
ABC transporter LinJ11_V3.0040 10,9 c LmjF11.0040 1,3
amino acid permease LinJ36_V3.0450 30,9 c LmjF36.0420 1,4
pteridine transporter LinJ06_V3.1320 2,8 c LmjF06.1260 1,6
Cellular component organization and biogenesis
LinJ16._V3.1550,
kinesin LinJ16_V3.1570 1,8 b LmjF16.1460 1,0
kinesin LinJ23_V3.0720 1,9 b LmjF23.0560 1,1
kinesin LinJ25_V3.2050 3,8 c LmjF25.1970 1,1
Cell cycle
cyclin-dependent kinase regulatory 
subunit
LinJ32_V3.3940 1,7 c LmjF32.3790 1,0
Cell communication
phosphoinositide-binding protein LinJ35_V3.2470 1,9 b LmjF35.2420 1,2
rab11B GTPase LinJ32_V3.1930 1,8 b LmjF32.1840 1,1
Unclassified
hypothetical LinJ02_V3.0430 4,3 b LmjF02.0460 1,4
hypothetical LinJ19_V3.0570 1,8 b LmjF19.0540 1,3
hypothetical LinJ19_V3.0610 1,8 b LmjF19.0610 1,1
hypothetical LinJ19_V3.1150 1,9 b LmjF19.1160 1,2
hypothetical LinJ20_V3.0030 3,6 b LmjF20.0030 1,1
hypothetical LinJ23_V3.0010 2,1 b LmjF23.0010 1,6
hypothetical LinJ23_V3.1170 2,2 b LmjF23.1000 1,3
hypothetical LinJ24_V3.2420 1,8 b LmjF24.2330 1,2
hypothetical LinJ27_V3.1110 2,5 b LmjF27.1230 1,3
hypothetical LinJ28_V3.0100 1,8 b LmjF28.0100 1,3
hypothetical LinJ32_V3.0530 1,7 b LmjF32.0500 1,3
hypothetical LinJ33_V3.1200 2,6 b LmjF33.1140 1,1
hypothetical LinJ33_V3.2570 1,8 b LmjF33.2440 1,0
Table 3: Genes differentially expressed in Leishmania infantum but constitutively expressed in Leishmania major. (Continued)BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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hypothetical LinJ35_V3.0180 1,8 b LmjF35.0180 1,3
hypothetical LinJ35_V3.4360 1,7 b LmjF35.4290 1,2
hypothetical LinJ36_V3.5520 2,9 b LmjF36.5290 1,1
A-1 LinJ29_V3.1020 2,4 c LmjF29.0935 1,6
dehydrogenase/oxidoreductase-like 
protein
LinJ02_V3.0700 2,0 c LmjF02.0730 1,2
EF hand-like protein LinJ13_V3.1490 1,9 c LmjF13.1450 1,3
ferric reductase transmembrane 
protein
LinJ30_V3.2050 2,0 c LmjF30.2050 1,2
GTPase activator protein LinJ29_V3.1670 7,1 c LmjF29.1560 1,1
leucine rich repeat protein LinJ28_V3.2790 5,5 c LmjF28.2580 1,0
lipin LinJ06_V3.0860 1,8 c LmjF06.0830 1,0
membrane-bound acid phosphatase LinJ28_V3.2850 2,2 c LmjF28.2650 1,4
zinc-finger protein LinJ30_V3.2350 2,4 c LmjF30.2340 1,1
metallopeptidase LinJ16_V3.0850 8,9 c LmjF16.0850 1,3
hypothetical LinJ01_V3.0820 2,3 c LmjF01.0800 1,0
hypothetical LinJ03_V3.0060 3,0 c LmjF03.0070 1,3
hypothetical LinJ04_V3.1150 7,7 c LmjF04.1140 1,3
hypothetical LinJ07_V3.0390 2,1 c LmjF07.0230 1,2
hypothetical LinJ08_V3.0170 1,9 c LmjF08.0160 1,1
hypothetical LinJ12_V3.0710 1,8 c LmjF12.1110 1,3
hypothetical LinJ13_V3.0230 2,7 c LmjF13.0230 1,2
hypothetical LinJ14_V3.0560 24,6 c LmjF14.0550 1,4
hypothetical LinJ15_V3.0510 8,5 c LmjF15.0490 1,0
hypothetical LinJ15_V3.1000 4,7 c LmjF15.0940 1,0
hypothetical LinJ16_V3.0620 5,2 c LmjF16.0620 1,3
hypothetical LinJ16_V3.1260 11,6 c LmjF16.1210 1,1
hypothetical LinJ17_V3.0600 2,4 c LmjF17.0540 1,1
hypothetical LinJ18_V3.0120 1,9 c LmjF18.0120 1,1
hypothetical LinJ18_V3.0300 3,0 c LmjF18.0300 1,1
hypothetical LinJ19_V3.1170 9,0 c LmjF19.1180 1,4
hypothetical LinJ20_V3.0450 1,8 c LmjF20.0380 1,1
hypothetical LinJ20_V3.1670 3,3 c LmjF20.1700 1,4
hypothetical LinJ21_V3.0920 4,6 c LmjF21.0825 1,1
hypothetical LinJ21_V3.1220 5,1 c LmjF21.0980 1,3
hypothetical LinJ22_V3.0110 1,8 c LmjF22.0240 1,2
hypothetical LinJ23_V3.1520 2,3 c LmjF23.1267 1,1
hypothetical LinJ24_V3.0700 8,2 c LmjF24.0690 1,5
hypothetical LinJ24_V3.1080 4,0 c LmjF24.1060 1,1
hypothetical LinJ24_V3.1620 1,9 c LmjF24.1550 1,1
hypothetical LinJ25_V3.0220 11,0 c LmjF25.0220 1,2
hypothetical LinJ25_V3.0460 5,0 c LmjF25.0450 1,4
hypothetical LinJ25_V3.0560 32,7 c LmjF25.0550 1,1
hypothetical LinJ26_V3.1260 1,9 c LmjF26.1280 1,0
hypothetical LinJ26_V3.1850 2,8 c LmjF26.1850 1,1
hypothetical LinJ26_V3.2220 6,5 c LmjF26.2210 1,2
hypothetical LinJ27_V3.1080 2,8 c LmjF27.1200 1,1
hypothetical LinJ29_V3.0930 46,7 c LmjF29.0868 1,5
hypothetical LinJ30_V3.0160 12,4 c LmjF30.0170 1,2
hypothetical LinJ31_V3.0490 5,4 c LmjF31.0470 1,3
hypothetical LinJ31_V3.1630 2,2 c LmjF31.1600 1,0
hypothetical LinJ32_V3.1410 2,2 c LmjF32.1350 1,1
hypothetical LinJ32_V3.3760 2,9 c LmjF32.3600 1,2
hypothetical LinJ33_V3.0590 1,8 c LmjF33.0565 1,3
hypothetical LinJ33_V3.0810 2,1 c LmjF33.0760 1,1
hypothetical LinJ33_V3.2850 1,9 c LmjF33.2710 1,4
hypothetical LinJ34_V3.2250 2,0 c LmjF34.2473 1,2
hypothetical LinJ34_V3.3520 4,1 c LmjF34.3730 1,1
hypothetical LinJ35_V3.4090 10,3 c LmjF35.4040 1,2
hypothetical LinJ35_V3.1640 9,4 c LmjF35.1640 1,2
hypothetical LinJ35_V3.5350 2,1 c LmjF35.5030 1,0
Table 3: Genes differentially expressed in Leishmania infantum but constitutively expressed in Leishmania major. (Continued)BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
Page 13 of 26
(page number not for citation purposes)
hypothetical LinJ36_V3.0470 6,3 c LmjF36.0440 1,1
hypothetical LinJ36_V3.4410 3,5 c LmjF36.4200 1,6
hypothetical LinJ36_V3.4940 1,8 c LmjF36.4710 1,1
a Only non-modulated genes are listed in this column.
b Genes differentially expressed in promastigotes.
c Genes differentially expressed in amastigotes.
Table 3: Genes differentially expressed in Leishmania infantum but constitutively expressed in Leishmania major. (Continued)
(~10%), the difference in expression levels between the
two methods (e.g. DNA microarray vs. qRT-PCR) was two-
fold or higher, however, both methods agreed on the dif-
ferential gene expression in the same life cycle stage (Table
5).
In this study, L. infantum amastigotes were isolated from
THP1-infected macrophages and L. major amastigotes
from mouse lesions. Our attempts to isolate sufficient
amastigote RNA material from the spleen/liver of infected
hamsters were unsuccessful due to low infection rates
obtained with the L. infantum strain we used in this study.
To investigate whether gene expression levels could be dif-
ferent in lesion- vs. THP1-derived amastigotes, we first
evaluated by qRT-PCR analysis the expression patterns of
a selected number of transcripts between L. major amastig-
otes isolated from mouse lesions or THP1 infected cells in
vitro. The majority of the genes tested (73%) were modu-
lated in a similar fashion in THP1-derived or lesion-
derived L. major amastigotes (see Additional file 5). Even
when  L. major or  L. infantum amastigotes were grown
within THP1-infected cells, different expression patterns
were obtained for the majority (67%) of the transcripts
analyzed by qRT-PCR (see Additional file 5). These results
further support our microarray data demonstrating sub-
stantial differences in amastigote-regulated gene expres-
sion between L. major and L. infantum (Figure 3).
Stage-regulated transcripts are distributed throughout the 
Leishmania spp. chromosomes
As mentioned in the Introduction, up to several hundred
Leishmania  genes are co-transcribed into polycistronic
RNAs, and individual mature mRNAs are resolved by
trans-splicing and polyadenylation [22,23]. To determine
genome distribution and chromosomal organization of
the differentially expressed genes in both Leishmania spe-
cies, global RNA expression profiles for both developmen-
tal stages of L. major and L. infantum were generated for
each of the 36 chromosomes (GeneDB, [19,20]). As rep-
resentative examples, only chromosomes 5, 16, 30 and 36
are shown here (Figure 4). This global genome analysis
revealed that differentially expressed genes in either life
stage are randomly distributed throughout Leishmania
chromosomes and that there is apparently no clustering of
these genes within specific genomic loci (Figure 4 and
data not shown). These observations are consistent with
published work to date and further support the concept
that stage-regulated gene expression in Leishmania
involves mostly post-transcriptional mechanisms.
SIDER retroposons and their distribution in the 3'UTR of 
Leishmania differentially expressed transcripts
We recently identified two large classes of distinct short
interspersed degenerate retroposons, named SIDER1
(~785 copies) and SIDER2 (~1073 copies) that are mainly
located in the 3'UTR of Leishmania mRNAs [46]. Members
of the SIDER1 subfamily correspond to the previously
identified ~450 nt 3'UTR element conserved in several
developmentally regulated mRNAs, including the amastin
mRNAs [15,47]. SIDER1 was shown to regulate amastin
mRNA translation in a stage-specific manner [47,48]
whereas SIDER2 plays a rather global role in mRNA deg-
radation [46]. Since SIDERs and especially SIDER2 are
involved in the regulation of mRNA stability, we investi-
gated whether these widespread retroposons were associ-
ated more frequently with differentially expressed
mRNAs. Therefore, we screened all differentially
expressed transcripts as determined by microarray experi-
ments in both Leishmania  species for the presence of
SIDER1 or SIDER2 homologous sequences in their poten-
tial 3'UTR (putative 3'UTRs were mapped using bioinfor-
matics tools as described [46,49]). On average, 21% of the
promastigote-upregulated transcripts and 26–42% of the
amastigote-upregulated transcripts in either species con-
tained either SIDER1 or SIDER2 in their 3'UTR (Table 6).
The higher percentage of SIDER1 in amastigotes can be
partly explained by the presence of this subclass of retro-
posons in amastin mRNAs that are part of a large gene
family ([15], unpublished data)). Interestingly, L. major
amastigote-upregulated transcripts contained generally a
higher percentage of SIDER1/2 retroposons and especially
SIDER1 compared to L. infantum (42% vs. 26%). Consid-
ering that ~25% of the L. major or L. infantum transcripts
bear either SIDER1 or SIDER2 in their 3'UTR (Table 6)
([46] (Smith, M. et al., unpublished)), our data indicate
that SIDERs, at least in L. infantum, are not preferentially
associated with differentially upregulated transcripts,
which suggests that additional regulatory elements may
also contribute to the stage-specific accumulation of Leish-
mania mRNAs.
Discussion
This study provides an extensive analysis of genome-wide
expression profiling of the main developmental life stagesBMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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Table 4: Genes differentially expressed in Leishmania major but constitutively expressed in Leishmania infantum.
GO annotation (molecular 
function)
Accession number (GeneDB) Fold increase a Accession number (GeneDB) Fold increase
L. infantum L. major
Metabolic process
2-aminoethylphosphonate: 
pyruvateaminotransferase
LinJ03_V3.0400 1,0 LmjF03.0040 2,0 b
folylpolyglutamate synthetase LinJ36_V3.2740 1,1 LmjF36.2610 2,1 b
phosphatidylethanolaminen-
methyltransferase
LinJ31_V3.3250 1,3 LmjF31.3120 2,4 b
aldehyde dehydrogenase LinJ25_V3.1160 1,1 LmjF25.1120 3,7 c
arginase LinJ35_V3.1490 1,3 LmjF35.1480 2,8 c
Carbohydrate metabolic process
6-phospho-1-fructokinase LinJ29_V3.2620 1,4 LmjF29.2510 2,6 b
aldose 1-epimerase LinJ35_V3.0990 1,1 LmjF35.0970 3,2 b
beta-fructofuranosidase LinJ04_V3.0300 1,3 LmjF04.0310 5,4 b
beta-fructofuranosidase LinJ04_V3.0310 1,2 LmjF04.0320 3,6 b
LinJ35_V3.0640,
beta-fructofuranosidase LinJ35_V3.0650 1,6 LmjF35.0640 5,9 b
LinJ21_V3.0300, LmjF21.0240,
hexokinase LinJ21_V3.0310 1,2 LmjF21.0250 2,2 b
glyceraldehyde 3-phosphate 
dehydrogenase
LinJ36_V3.2480 1,4 LmjF36.2350 3,6 c
Lipid metabolic process
farnesyl pyrophosphate synthase LinJ22_V3.1210 1,2 LmjF22.1360 1,9 b
fatty acid elongase LinJ14_V3.0670 1,6 LmjF14.0650 2,7 b
mevalonate kinase LinJ31_V3.0580 1,1 LmjF31.0560 2,1 b
phospholipase c-like LinJ30_V3.2970 1,3 LmjF30.2950 2,1 c
polyprenyl synthase LinJ19_V3.0210 1,0 LmjF19.0220 2,4 c
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
adenosine deaminase LinJ35_V3.2200 1,1 LmjF35.2160 4,6 b
DNA metabolic process
j-binding protein LinJ14_V3.0040 1,4 LmjF14.0040 2,3 b
RNA metabolic process
RNA-binding protein LinJ23_V3.0900 1,3 LmjF23.0730 3,6 c
Amino acid and derivative metabolic process
tyrosine aminotransferase LinJ36_V3.2490 1,1 LmjF36.2360 2,7 b
Protein metabolic process
lipophosphoglycan biosynthetic 
protein
LinJ29_V3.0790 1,3 LmjF29.0760 2,3 b
Proteolysis
calpain-like cysteine peptidase LinJ20_V3.1230 1,1 LmjF20.1190 2,6 bBMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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calpain-like cysteine peptidase LinJ27_V3.0510 1,3 LmjF27.0510 2,8 b
carboxypeptidase LinJ33_V3.2670 1,6 LmjF33.2540 3,0 b
carboxypeptidase LinJ13_V3.0090 1,1 LmjF13.0090 2,1 b
glutamamyl carboxypeptidase LinJ29_V3.1680 1,1 LmjF29.1570 1,7 b
oligopeptidase b LinJ09_V3.0820 1,1 LmjF09.0770 2,2 b
pyroglutamyl-peptidase (PGP) LinJ34_V3.1750 1,4 LmjF34.2000 2,0 b
cysteine protease LinJ19_V3.1460 1,3 LmjF19.1420 3,1 c
Protein folding
chaperone protein DNAJ LinJ32_V3.3220 1,1 LmjF32.3030 2,2 b
Protein modification process
protein kinase LinJ26_V3.2600 1,2 LmjF26.2570 4,3 b
protein kinase LinJ21_V3.0190 1,1 LmjF21.0130 2,2 b
mitogen-activated protein kinase 3 LinJ10_V3.0540 1,0 LmjF10.0490 2,0 b
serine/threonine-protein kinase LinJ31_V3.3070 1,1 LmjF31.2960 2,8 b
serine/threonine-protein phosphatase 
PP1
LinJ34_V3.0850 1,1 LmjF34.0810 1,8 b
protein kinase LinJ36_V3.4460 1,6 LmjF36.4250 1,7 c
Electron transport
D-lactate dehydrogenase LinJ29_V3.0290 1,1 LmjF29.0280 3,0 b
pyrroline-5-carboxylate reductase LinJ13_V3.1420 1,6 LmjF13.1680 2,1 b
UDP-galactopyranose LinJ18_V3.0200 1,1 LmjF18.0200 1,7 b
Transport
amino acid permease LinJ27_V3.0530 1,6 LmjF27.0680 3,0 b
biopterin transporter LinJ35_V3.5120 1,1 LmjF35.5150 2,4 b
LmjF36.6280,
glucose transporter, lmgt2 LinJ36_V3.6550 1,0 LmjF36.6290 5,6 b
pteridine transporter LinJ06_V3.0310 1,1 LmjF06.0310 3,2 b
sugar transporter LinJ24_V3.0690 1,0 LmjF24.0680 3,9 b
transmembrane amino acid 
transporter
LinJ07_V3.1340 1,1 LmjF07.1160 9,7 b
LinJ15_V3.1230,
LinJ15_V3.1240,
LinJ15_V3.1250, LmjF15.1230,
nucleoside transporter 1 LinJ15_V3.1260 1,2 LmjF15.1240 4,5 b
mitochondrial ornithine transporter 
1-like
LinJ16_V3.0220 1,0 LmjF16.0210 2,2 b
Cell component organization and biogenesis
dynein heavy chain LinJ36_V3.1010 1,6 LmjF36.0950 2,6 b
kinesin LinJ14_V3.0870 1,1 LmjF14.0810 1,8 b
kinesin LinJ21_V3.1280 1,4 LmjF21.1040 1,9 b
LmjF09.0150,
LmjF09.0154,
LmjF09.0158,
LmjF09.0162,
LmjF09.0166,
LmjF09.0170,
microtubule associated protein LinJ09_V3.0180 1,3 LmjF09.0174 2,5 b
LinJ19_V3.0820,
microtubule associated protein LinJ19_V3.0850 1,1 LmjF19.0860 2,5 b
PFR LinJ05_V3.0920 1,3 LmjF05.0920 2,3 b
PFR par4 LinJ05_V3.0040 1,3 LmjF05.0040 2,8 b
Table 4: Genes differentially expressed in Leishmania major but constitutively expressed in Leishmania infantum. (Continued)BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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Cell communication
cAMP specific phosphodiesterase LinJ15_V3.1550 1,5 LmjF15.1480 1,8 b
phosphodiesterase LinJ18_V3.1100 1,4 LmjF18.1090 2,3 b
Cell motility
myosin heavy chain LinJ32_V3.4020 1,6 LmjF32.3870 3,5 b
Unclassified
acid phophatase LinJ36_V3.2600 1,0 LmjF36.2470 1,9 b
long chain fatty Acyl CoA synthetase LinJ03_V3.0220 1,1 LmjF03.0230 1,9 b
LinJ19_V3.1350, LmjF19.1340,
glycerol uptake protein LinJ19_V3.1360 1,3 LmjF19.1345 1,8 b
membrane-bound acid phosphatase 2 LinJ36_V3.2720 1,1 LmjF36.2590 4,6 b
nons pecific nucleoside hydrolas e LinJ18_V3.1570 1,1 LmjF18.1580 2,1 b
prostaglandin f2-alpha synthase LinJ31_V3.2210 1,5 LmjF31.2150 5,1 b
LinJ31_V3.0950, Lm jF 31.0920,
s odium s tibogluconate res is tance 
protein
LinJ31_V3.3400 1,4 LmjF31.0950 2,1 b
s urfac e antigen-lik e LinJ04_V3.0170 1,0 Lm jF04.0180 2,0 b
s urfac e antigen-lik e LinJ04_V3.0180 1,0 Lm jF04.0190 2,7 b
Lm jF 12.0850,
Lm jF 12.0860,
Lm jF 12.0870,
surface antigen 2 LinJ12_V3.0020 1,2 LmjF12.0890 2,1 b
ubiquitin-conjugating enzy me-like LinJ21_V3.0500 1,6 Lm jF21.0440 2,2 b
hypothetical LinJ03_V3.0340 1,4 Lm jF03.0360 1,9 b
Lm jF 04.0130,
Lm jF 04.0140,
Lm jF 04.0150,
Lm jF 04.0160,
hypothetical LinJ04_V3.0160 1,1 LmjF04.0170 2,9 b
hypothetical LinJ05_V3.1070 1,3 Lm jF05.1070 3,0 b
hypothetical LinJ09_V3.1360 1,0 Lm jF09.1300 2,0 b
hypothetical LinJ09_V3.1600 1,4 Lm jF09.1510 2,9 b
hypothetical LinJ09_V3.1610 1,1 Lm jF09.1520 3,2 b
Lm jF 11.0670,
LinJ11_V3.0680, Lm jF 11.0673,
hypothetical LinJ11_V3.0690 1,0 LmjF11.0675 3,0 b
hypothetical LinJ04_V3.1220 1,3 Lm jF04.1200 2,0 b
LinJ14_V3.0490, Lm jF 14.0480,
hypothetical LinJ14_V3.0500 1,3 LmjF14.0490 2,6 b
hypothetical LinJ15_V3.0560 1,0 Lm jF15.0540 1,9 b
hypothetical LinJ17_V3.0690 1,4 Lm jF17.0630 2,5 b
hypothetical LinJ17_V3.0990 1,1 Lm jF17.0890 6,5 b
hypothetical LinJ18_V3.1300 1,1 Lm jF18.1320 1,9 b
hypothetical LinJ19_V3.0070 1,4 Lm jF19.0080 3,5 b
hypothetical LinJ23_V3.0890 1,3 Lm jF23.0720 2,4 b
hypothetical LinJ23_V3.1020 1,1 Lm jF23.0840 2,6 b
hypothetical LinJ23_V3.1730 1,4 Lm jF23.1690 1,8 b
hypothetical LinJ24_V3.1110 1,1 Lm jF24.1090 4,6 b
hypothetical LinJ25_V3.2090 1,1 Lm jF25.2010 2,7 b
hypothetical LinJ26_V3.1980 1,5 Lm jF26.1980 1,9 b
hypothetical LinJ28_V3.0220 1,1 LmjF28.0220 1,7 b
hypothetical LinJ28_V3.0420 1,2 LmjF28.0280 1,8 b
hypothetical LinJ29_V3.1820 1,0 Lm jF29.1690 2,8 b
hypothetical LinJ29_V3.2550 1,6 Lm jF29.2440 3,3 b
hypothetical LinJ30_V3.1230 1,1 Lm jF30.1170 2,5 b
hypothetical LinJ30_V3.2700 1,3 Lm jF30.2700 3,3 b
Table 4: Genes differentially expressed in Leishmania major but constitutively expressed in Leishmania infantum. (Continued)BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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hypothetical LinJ32_V3.0480 1,3 LmjF32.0470 2,0 b
hypothetical LinJ32_V3.1760 1,4 Lm jF32.1680 3,3 b
hypothetical LinJ32_V3.3350 1,3 Lm jF32.3150 2,3 b
hypothetical LinJ32_V3.3650 1,3 Lm jF32.3450 1,9 b
hypothetical LinJ33_V3.0220 1,6 Lm jF33.0210 4,0 b
hypothetical LinJ33_V3.1040 1,0 Lm jF33.0990 3,4 b
hypothetical LinJ33_V3.1130 1,4 LmjF33.1070 2,7 b
hypothetical LinJ33_V3.2940 1,4 LmjF33.2800 1,7 b
hypothetical LinJ34_V3.0210 1,1 LmjF34.0190 2,1 b
hypothetical LinJ34_V3.0740 1,2 LmjF34.0705 1,8 b
hypothetical LinJ34_V3.4110 1,0 LmjF34.4280 2,4 b
hypothetical LinJ35_V3.1470 1,0 LmjF35.1460 1,7 b
hypothetical LinJ35_V3.5400 1,2 LmjF35.5080 1,7 b
hypothetical LinJ36_V3.0730 1,0 LmjF36.0670 2,5 b
hypothetical LinJ36_V3.1190 1,0 LmjF36.1130 1,7 b
hypothetical LinJ36_V3.1230 1,3 LmjF36.1170 2,1 b
hypothetical LinJ36_V3.1520 1,1 LmjF36.1460 1,7 b
hypothetical LinJ36_V3.4470 1,1 LmjF36.4260 2,0 b
Lm jF30.1410,
Lm jF30.1420,
ama 1 LinJ30_V3.1490 1,1 LmjF30.1430 2,1 c
Lm jF31.1450,
s urfac e membrane protein gp46-like LinJ31_V3.1490 1,1 LmjF31.1460 2,1 c
hypothetical LinJ06_V3.0030 1,1 LmjF06.0030 2,0 c
hypothetical LinJ17_V3.0390 1,3 LmjF17.0340 4,0 c
hypothetical LinJ18_V3.1110 1,1 LmjF18.1100 1,7 c
hypothetical LinJ19_V3.1540 1,1 LmjF19.1490 1,8 c
hypothetical LinJ20_V3.1630 1,1 LmjF20.1660 2,0 c
hypothetical LinJ24_V3.0590 1,2 LmjF24.0580 4,8 c
hypothetical LinJ25_V3.0230 1,3 LmjF25.0230 2,0 c
hypothetical LinJ26_V3.1500 1,3 LmjF26.1520 3,5 c
hypothetical LinJ28_V3.1070 1,4 LmjF28.0980 2,6 c
hypothetical LinJ28_V3.2860 1,2 LmjF28.2660 2,0 c
hypothetical LinJ31_V3.2910 1,4 LmjF31.2810 2,1 c
hypothetical LinJ32_V3.2620 1,3 LmjF32.2480 1,8 c
hypothetical LinJ35_V3.4870 1,3 LmjF35.4810 1,8 c
hypothetical LinJ36_V3.2960 1,1 LmjF36.2820 1,9 c
hypothetical LinJ36_V3.3480 1,3 LmjF36.3320 1,7 c
hypothetical LinJ36_V3.4870 1,0 LmjF36.4640 2,0 c
a Only non-modulated genes are listed in this column.
b Genes differentially expressed in promastigotes.
c Genes differentially expressed in amastigotes.
Table 4: Genes differentially expressed in Leishmania major but constitutively expressed in Leishmania infantum. (Continued)
(e.g. procyclic promastigotes and intracellular amastig-
otes) of L. infantum along with a comparative analysis of
gene expression profiles between L. infantum and L. major,
two species causing distinct pathologies in humans, using
a multispecies Leishmania DNA microarray. The compara-
tive analysis between L. major and L. infantum transcrip-
tomes is the first to date and may lead to a better
understanding of how differential gene expression among
species with high similarity in genome sequences may be
involved in the development of different disease pheno-
types.
Expression patterns, stage-regulated genes and pathways 
identified
Genes whose expression was upregulated in either pro-
mastigote or amastigote life stages of L. major and L. infan-
tum,  as determined by DNA microarrays, belong to
various biological processes. Approximately 25% of the
differentially expressed genes between both life stages in
both species are involved in metabolism (Figure 2). Pro-
mastigotes and amastigotes reside in different environ-
ments and it is therefore expected that their metabolic
needs will differ. Promastigotes in the sand fly use glycol-
ysis and mitochondrial metabolism as their main energy
sources (reviewed in [50]). Amastigotes contain glyco-
somes, although considerably fewer than promastigotes
[50]. L. mexicana amastigotes isolated from mouse lesions
have a reduced need for proline and glucose consumption
and increased beta-oxidation of fatty acids compared to
promastigotes, which could be used as energy source
[51,52]. Our study revealed indeed that genes involved in
carbohydrate metabolism as well as several glucose trans-BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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porters were overexpressed in promastigotes compared to
amastigotes (Table 2, see Additional files 1 and 1). Inter-
estingly, recent proteomic studies using axenic L. donovani
promastigote and amastigote cultures indicated that the
differentiating parasite shifts from glucose to fatty acids
and amino acids as its main energy source [53]. Enzymes
required for the de novo synthesis of inositol and mannose
are important for amastigote growth [54]. In agreement
with this, the myo-inositol-1-phosphate synthetase gene
encoding a key enzyme in the first step of inositol synthe-
sis was found upregulated in both L. major and L. infantum
amastigotes (Table 2).
The absence of the glyoxylate pathway in Leishmania,
which is required for the conversion of acetyl-CoA into
sugars, indicates that amastigotes may be unable to utilize
fatty acids as their major carbon source [19,55]. Amino
acids are the second carbon source for Leishmania promas-
tigotes but are also important in the amastigote stage [56-
58]. The phagolysosomes of macrophages contain high
levels of amino acids generated by proteolytic digestion of
host phagosomal proteins and from exogenous proteins
delivered into the phagolysosome via endocytosis
[54,59]. Consistently, several lysosomal aminopeptidases
and cathepsin-L like cysteine proteinases were upregu-
lated in amastigotes (see Additional files 2 and 4). Also,
several amino acid transporters and permeases important
for the transport of amino acids from the phagosome into
amastigotes were found upregulated in amastigotes (see
Additional files 2 and 4 and [58]). Leishmania amastigotes
can scavenge all their purine requirements, cations, vita-
mins, carbon sources and several essential amino acids
from the macrophage phagolysosome via plasma mem-
brane transporters [56]. Consistent with this, intracellular
amastigotes of both L. major and L. infantum overexpress
a relatively larger number of membrane transporters than
promastigotes (see Additional files 2 and 4).
Important differences were observed in the expression of
genes involved in cellular organization, biogenesis and
cell motility between promastigote and amastigote stages
of both Leishmania species. The motile flagellated promas-
tigotes as opposed to the aflagellated amastigotes overex-
press dyneins corresponding to large minus-end-directed
microtubule motors providing the force for flagellar
movement [30,31], microtubules and a variety of micro-
tubule-associated proteins [60], kinesins and the trypano-
somatid-specific PFR genes (Table 2, Additional files 1
and 3). The genes coding for microtubule-associated pro-
teins were found upregulated in L. major but surprisingly
not in L. infantum promastigotes (Table 4). The genes cod-
ing for calpains, calcium-dependent cysteine proteinases
participating in a variety of cellular processes, including
cytoskeletal/membrane attachments and signal transduc-
tion pathways [61], were upregulated in L. major and L.
Table 5: Comparison of microarray mRNA expression levels to 
relative expression levels determined by quantitative real time 
PCR (qRT-PCR).
Accession number (GeneDB) Ratio Ama/Pro
DNA Microarrays a qRT-PCR b
L. infantum
LinJ30_V 3.2870 0,2 0,5 ± 0,0
LinJ34_V 3.0070 0,3 0,5 ± 0,0
LinJ36_V 3.5620 0,4 0,3 ± 0,0
LinJ21_V 3.1490 0,4 0,5 ± 0,1
LinJ14_V 3.1240 0,4 0,5 ± 0,1
LinJ23_V 3.0860 0,5 0,3 ± 0,0
LinJ25_V 3.0500 0,5 0,2 ± 0,2
LinJ16_V 3.0950 0,5 0,5 ± 0,0
LinJ18_V 3.1090 0,5 0,6 ± 0,0
LinJ24_V 3.0870 0,6 0,5 ± 0,0
LinJ30_V 3.1520 1,7 2,2 ± 0,3
LinJ33_V 3.2470 1,8 1,3 ± 0,1
LinJ34_V 3.1730 2,0 2,3 ± 0,3
LinJ30_V 3.2050 2,0 1,8 ± 0,1
LinJ34_V 3.1160 2,3 1,9 ± 0,6
LinJ31_V 3.0370 2,4 2,2 ± 0,3
LinJ14_V 3.1450 2,4 3,7 ± 0,3
LinJ34_V 3.1020 c 2,8 10,1 ± 0,5
LinJ30_V 3.0560 4,1 3,3 ± 0,3
LinJ27_V 3.0100 4,6 3,7 ± 0,4
LinJ19_V 3.0420 5,0 3,0 ± 0,3
LinJ36_V 3.6530 5,0 1,9 ± 0,2
LinJ23_V 3.1790 7,0 2,4 ± 0,5
LinJ36_V 3.0130 7,3 4,2 ± 0,3
LinJ31_V 3.2790 7,6 2,0 ± 0,1
LinJ26_V 3.0040 8,1 2,4 ± 0,2
LinJ36_V 3.4180 8,7 6,1 ± 0,6
LinJ34_V 3.4270 20,2 2,4 ± 0,2
LinJ14_V 3.1500 22,0 1,2 ± 0,1
LinJ14_V 3.0560 24,6 2,0 ± 0,0
LinJ36_V 3.2480 0,7 0,6 ± 0,3
LinJ14_V 3.0760 0,9 1,5 ± 0,1
LinJ25_V 3.1160 0,9 1,0 ± 0,1
LinJ07_V 3.0550 1,0 1,6 ± 0,2
LinJ28_V 3.0470 1,0 1,2 ± 0,1
LinJ34_V 3.1910 1,0 1,0 ± 0,5
LinJ19_V 3.0010 1,2 1,6 ± 0,1
LinJ34_V 3.2420 1,2 1,3 ± 0,1
LinJ30_V 3.2200 1,3 1,3 ± 0,1
LinJ36_V 3.4000 1,4 1,8 ± 0,3
LinJ17_V 3.0440 1,5 3,0 ± 0,2
LinJ08_V 3.1220 1,6 1,7 ± 0,1
L. major
Lm jF33.2340 0,5 0,3 ± 0,0
Lm jF36.1360 0,5 0,8 ± 0,0
Lm jF29.2510 0,4 0,02 ± 0,00
Lm jF36.2360 0,4 0,4 ± 0,0
Lm jF06.0310 0,3 0,4 ± 0,0
Lm jF35.0970 0,3 0,6 ± 0,0
Lm jF23.0690 0,3 0,2 ± 0,0
Lm jF23.1300 0,3 0,1 ± 0,0BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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infantum promastigotes (Table 2). In contrast, intracellu-
lar amastigotes upregulated the expression of the lyso-
somal cathepsin-L like cysteine proteinases or
aminopeptidases (see Additional files 2 and 4).
Species-specific differential gene expression
Comparative analyses of the complete genomes of L.
major,  L. infantum and  L. braziliensis causing distinct
human diseases revealed marked sequence conservation
and synteny (e.g. more than 99% of genes between the
three genomes were syntenic and conservation within
coding sequences was 82–94%) [20]. Despite the 20–100
million years of divergence within the Leishmania genus
and the broad difference in disease pathologies, only 78
genes were found to be species-specific; 5 L. major-specific,
26 L. infantum-specific and 47 L. braziliensis-specific [20].
Remarkably, our studies revealed that some of these
unique species-specific genes, all encoding hypothetical
proteins, were also developmentally regulated. For exam-
ple, LinJ22_V3.0670 only present in L. infantum, or
LinJ34_V3.3430, LinJ15_V3.0620, LinJ16_V3.1460, and
LinJ31_V3.1180 present in L. infantum but pseudogenes
in L. major [20] were expressed preferentially in the amas-
tigote stage (see Additional file 2). The L. major unique
genes LmjF04.1020 and LmjF32.2470 were differentially
expressed in promastigotes and amastigotes, respectively.
The L. major promastigote-regulated genes LmjF10.0185
and LmjF27.0870 are pseudogenes in L. infantum (see
Additional file 3). Few of these genes are also present in L.
braziliensis  although their developmental regulation, if
any, is not known. Interestingly, the L. donovani A2 genes
(pseudogenes in L. major), the only genes implicated so
far in disease tropism [62], are specifically expressed in
amastigotes [11]. These data suggest that both parasite
genome differences and differential expression of species-
specific genes may contribute to species-specific tropism.
The comparative transcriptomic analyses between L. major
and L. infantum showed that only 10–12% of the differen-
tially expressed genes in either life stage were common to
both species. Commonly upregulated genes may fulfill
essential features of the parasite such as metabolism,
motility, infectivity and interaction with the host. Consist-
ently, several metabolic genes, the amastigote-specific
amastin surface proteins, which may act as receptors or
transporters/channels [15] and the promastigote-upregu-
lated dyneins, paraflagellar rod components and calpain-
like cysteine peptidases were differentially upregulated in
both species. The family of receptor adenylase cyclases
(RAC) that play a role in signal transduction was differen-
tially upregulated both in L. major and L. infantum pro-
mastigotes (Table 2). This is consistent with the report
that rac-A and rac-B genes were expressed preferentially in
the insect stage of L. donovani [63]. However, the majority
of the differentially expressed genes in either life stage
were specific to each Leishmania species. Species-specific
differential gene expression may be attributed to a
dynamic mode of regulation, which is suitable to species-
specific adaptations to different insect vectors and life-
cycle features, different target tissues, and distinct disease
pathogenesis. Important differences in the stage-regulated
gene expression of RNA-binding proteins, amino acid
transporters, proteolytic enzymes, and protein kinases
were observed between L. major and  L. infantum. For
example, L. major amastigotes upregulate the expression
of important virulence genes encoding the lysosomal
cathepsin-L like cysteine proteinases of the papain super-
family [64] whereas L. infantum amastigotes overexpress
Lm jF02.0160 0,3 0,1 ± 0,0
Lm jF23.0710 0,2 0,1 ± 0,0
Lm jF35.2160 0,2 0,1 ± 0,0
Lm jF36.2590 0,2 0,1 ± 0,0
Lm jF21.0240 0,2 0,2 ± 0,0
Lm jF31.0350 0,2 0,1 ± 0,0
Lm jF04.0310 0,2 0,3 ± 0,0
Lm jF07.1160 0,1 0,1 ± 0,0
Lm jF31.2460 2,6 2,3 ± 0,2
Lm jF28.2910 2,8 1,9 ± 0,2
Lm jF36.5960 3,1 2,0 ± 2,1
Lm jF23.0730 3,6 1,1 ± 0,1
Lm jF36.2350 3,6 4,5 ± 0,4
Lm jF25.1120 3,7 2,3 ± 0,3
Lm jF08.0820 4,3 6,6 ± 0,9
Lm jF14.1360 4,7 4,4 ± 0,4
Lm jF30.2190 5,8 3,0 ± 0,1
Lm jF11.1220 6,7 5,2 ± 0,3
Lm jF34.1840 7,3 3,1 ± 0,2
Lm jF35.4230 10,3 1,9 ± 0,1
Lm jF31.3190 10,9 3,7 ± 0,4
Lm jF36.3810 1,0 1,1 ± 0,1
Lm jF28.0330 1,1 1,3 ± 0,2
Lm jF30.2050 1,2 1,5 ± 0,2
Lm jF03.0570 1,0 1,2 ± 0,2
Lm jF34.4510 1,0 2,0 ± 0,2
Lm jF34.0070 1,6 1,0 ± 0,1
a The microarray results have all a p-value lower than 0.05.
b The same RNA preparations were used for the microarray and qRT-
PCR experiments. Levels of mRNA determined by qRT-PCR were 
normalized as described in Methods. The values reported here are 
the average of two biological replicates and three technical replicates. 
The set of primers for qRT-PCR amplification are presented in 
Additional file 6.
c LinJ34_V3.1020 encodes an amastin homologue that shares 
homology to other members of the amastin gene family. For the 
microarray experiment, the 70-mer probe used recognizes more than 
one amastin members whereas the set of primers used for qRT-PCR 
was specific to the LinJ34_V3.1020 gene only.
d LinJ14_V3.1500 is a member of the glycosylation phosphoglycan beta 
1,3 galactosyltransferase gene family. For the microarray experiment 
the 70-mer probe used recognizes more than one gene family 
members whereas the set of primers used for qRT-PCR was specific 
to the LinJ14_V3.1500 gene only, whose expression was not 
modulated.
Table 5: Comparison of microarray mRNA expression levels to 
relative expression levels determined by quantitative real time 
PCR (qRT-PCR). (Continued)BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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genes encoding aminopeptidases, which catalyze the
removal of N-terminal amino acid residues from peptides
and proteins, as well as the subtilisin-like serine peptidase
and the hslvu complex proteolytic subunit (see Additional
files 2 and 4). Members of the surface antigen proteins 2
(or GP46) are upregulated in L. major promastigotes but
not in L. infantum promastigotes (Tables 3, 4 and Addi-
tional files 1 and 4).
It is likely that lesion-derived amastigotes and amastigotes
isolated from in vitro-infected macrophages display some
differences in the expression of genes, especially those
that can be modulated by the immune status of the host
and/or gene products that contribute together with host
factors to the establishment of the disease. However, the
majority of modulated genes whose functions are impor-
tant or essential for the parasite's differentiation into its
amastigote form and for the survival of amastigotes
within the phagolysosome of macrophages should in
principle be modulated similarly in lesion-derived or in
vitro-infected macrophages given that amastigotes iso-
lated from THP1 at 4–5 days following infection are fully
differentiated and divide within the phagolysosome. The
substantial differences that we observed in stage-regulated
gene expression not only for amastigotes but also for pro-
mastigotes, which were cultured under the same condi-
tions, between L. infantum and L. major may be attributed
for the most part to species-specific factors. In line with
Distribution of differentially expressed transcripts in chromosomes 5, 16, 30 and 36 of Leishmania major and Leishmania infan- tum Figure 4
Distribution of differentially expressed transcripts in chromosomes 5, 16, 30 and 36 of Leishmania major and 
Leishmania infantum. On the horizontal axis are all genes in the order found on the selected chromosomes according to 
GeneDB [24]. On the vertical axis is the amastigote (Ama) to promastigote (Pro) expression ratio. Genes upregulated in the 
amastigote stage are above the line at 0.75 and genes upregulated in promastigotes are below the line -0.75. Blue dots repre-
sent stage-regulated expression of genes on the respective L. infantum chromosomes and black dots represent differential 
expression of genes on the same chromosomes of L. major.BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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this possibility are recent observations from our labora-
tory indicating that gene orthologues between L. major
and L. infantum can be regulated in a different manner
implying either distinct 3'UTR elements or possibly regu-
latory factors that are only expressed in one of the species
(Müller et al., unpublished). In further agreement with
our findings, is a recent interspecies microarray analysis
comparing lesion-derived amastigotes of L. major and L.
mexicana,  two species causing cutaneous leishmaniasis,
which demonstrated substantial differences in RNA
expression profiles. Indeed, only 15% of the differentially
expressed genes in promastigotes were in common
between L. major and L. mexicana and there were no amas-
tigote-upregulated genes shared by the two species [65].
We showed here, and others have reported previously [25-
29], that a small percentage of genes (7–9%) are regulated
at the RNA level throughout the life cycle stages of Leish-
mania. This percentage of modulated genes is not negligi-
ble if one considers that regulation of gene expression in
Leishmania occurs at different levels. Several proteomics
studies reported a higher amount of genes (12–18%)
being regulated in a stage-specific manner at the transla-
tional and posttranslational levels [65-67]. It has also
been reported that a modest correlation exists between
mRNA and protein levels [66]. This modest correlation
could be partly explained by the presence of multiple ele-
ments within the 3'UTR of Leishmania transcripts, which
often have distinct functions on either mRNA stability or
translation [46,48,68].
Do stage-regulated transcripts share common regulatory 
motifs in their 3'UTR?
It is now well established that stage-specific regulation of
gene expression in Leishmania is predominantly mediated
by elements in the 3'UTR of mRNAs (reviewed in
[22,23]). In few cases, specific regions within 3'UTRs have
been delineated as cis-elements but their mechanism of
action remains for the most part unknown. We recently
reported the presence of two classes of distinct short inter-
spersed degenerate retroposons, SIDER1 and SIDER2 that
are widely distributed in the 3'UTR of a large number of
Leishmania  mRNAs (Table 6) [46]. We showed that
SIDER1 and SIDER2 have distinct regulatory functions
involving either mRNA translational control or RNA deg-
radation, respectively [46-48]. SIDERs were the first con-
served regulatory elements found in numerous Leishmania
transcripts. However, the distribution of SIDERs among
differentially expressed transcripts was not significantly
higher from their global distribution among Leishmania
transcripts (~25%) (Table 6) [46] (Smith, M. et al., unpub-
lished). SIDER1-mediated regulation occurs at the level of
translation and does not necessarily affect mRNA abun-
dance [48]. In the few cases studied, SIDER2 seems to be
involved in the degradation of generally short-lived
mRNAs. Rapid mRNA turnover may permit the parasite to
adapt to the continuously changing physiological needs
within its invertebrate and mammalian host, and these
temporal changes may not be detectable under our exper-
imental conditions. Hence, SIDERs might participate in
more dynamic regulatory processes throughout the Leish-
mania  life cycle in response to specific environmental
stimuli, yet to be analyzed. It is likely that additional
3'UTR elements should regulate stability of the differen-
tially expressed transcripts in Leishmania. For example, we
have recently identified a U-rich element in the amastin
3'UTR that contributes to the amastin mRNA degradation
specifically in promastigotes [68].
Conclusion
In conclusion, whole-genome analyses of inter-stage and
inter-species RNA expression profiles between L. major
and  L. infantum promastigote and amastigote develop-
mental forms highlighted that only a small percentage of
Leishmania transcripts are modulated during development
and most importantly that Leishmania species causing dis-
tinct pathologies express a diverse set of differentially
expressed transcripts. These important differences in
stage-regulated gene expression between species may be
necessary to allow species-specific adaptations to different
insect vectors and life-cycle features and could contribute
to disease tropism. It is possible that in order to diversify
and/or to enlarge their expression profile patterns in
response to continuously changing environments
Table 6: Distribution of SIDER retroposons among differentially expressed Leishmania spp. transcripts.
Differentially Expressed Transcriptsa Genomic Distributionb
Species Life Stage SIDER1% SIDER2% SIDER1% SIDER2%
L. major amastigote 23.9 18.3 11.6 15.0
promastigote 10.6 11.6
L. infantum amastigote 14.1 11.9 9.4 15.8
promastigote 8.4 12.4
a As determined by the DNA microarray experiments (this study).
b Refined species-specific hidden Markov model profiles were used to determine the genomic distribution of two SIDER families in L. infantum and L. 
major ([46]; Smith et al. unpublished)). Values represent the proportion of annotated coding sequences that potentially harbor at least one SIDER 
element in their 3'UTR. The percentage of SIDERs in differentially expressed transcripts is compared with the genomic distribution of SIDERs.BMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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throughout development, Leishmania  species have
adopted a dynamic, multilayered and complex mode of
regulating gene expression. The results presented in this
study favor this possibility.
Methods
Leishmania strains, cell culture and differentiation
The L. infantum MHOM/MA/67/ITMAP-263 and L. major
LV39 MRHO/SU/59/P strains used in this study have been
previously described [69,70]. L. infantum and L. major pro-
mastigotes were cultured at pH 7.0 and 25°C in SDM-79
medium [71] supplemented with 10% heat-inactivated
fetal calf serum (Multicell, Wisent Inc) and 5 μg/ml
hemin. L. infantum amastigotes were cultured in a human
leukemia monocyte cell line (THP-1 cells) as described
previously [72]. THP-1 cells in the log phase of growth
were differentiated by incubation for 2 days in medium
containing 20 ng of phorbol myristate acetate/ml
(Sigma). THP-1 cells were then washed with pre-warmed
medium and subsequently infected with stationary-phase
L. infantum promastigotes in flat bottom tissue culture
flasks (75 cm2) at a parasite/macrophage ratio of 15:1.
After two hours, non-internalized parasites were removed
by several washes, and infected macrophages were incu-
bated for 4 days. L. major amastigotes were also cultured
in THP-1 using the same protocol. L. major lesion amastig-
otes were obtained from the infected footpad of BALB/c
mice 6–8 weeks post-infection as previously described
[70].
RNA extraction and cDNA sample preparation
Infected macrophages were incubated with cold HEPES-
NaCl-0.0125% SDS for few minutes and neutralized with
cold HEPES-NaCl. After centrifugation at 3000 rpm, mac-
rophages were resuspended in cold HEPES-NaCl and, on
ice passed 10 times in syringes equipped with a 27G1/2
needle to obtain pure amastigotes free of macrophage
material. Amastigotes were washed once in cold HEPES-
NaCl and total RNA was prepared using RNeasy Plus
(Qiagen) as instructed by the manufacturer. L. major
lesion amastigotes were extracted from macrophages
using the same procedure as above. Total RNA from pro-
mastigotes grown to mid log phase was prepared using
RNeasy Plus directly. RNA was treated with Turbo DNAse-
free (Ambion). The quality and quantity of RNA were
assessed using RNA 6000 Nano Assay Chips (Agilent
Technologies). The presence of three distinct ribosomal
peaks (18S, 24Sα and 24Sβ) confirmed successful RNA
extraction and no detectable macrophage RNA in the L.
infantum  and  L. major amastigote RNA preparations.
Complementary DNA (cDNA) was generated from 5 μg of
total RNA using a random primer hexamer (GE Health-
care) and aminoallyl-dUTP mix (Sigma) following the
protocol for Superscript III (Invitrogen). After 5 hours of
incubation at 50°C, the RNA was hydrolyzed with NaOH
and EDTA for 15 min at 65°C, then pH was neutralized
with HCl. cDNA was purified from unincorporated ami-
noallyl-dUTP with MinElute PCR Purification columns
(Qiagen), phosphate wash buffer (5 mM KPO4 pH 8.0,
80% EtOH) and phosphate elution buffer (4 mM KPO4
pH 8.5).
L. infantum and L. major DNA oligonucleotide full 
genome microarray design
The recent completion of the sequence of the L. major [19]
and L. infantum genomes [20] allowed the generation of
multispecies high-density oligonucleotide microarrays.
The genome of both species was first compared using
BLAST and genes on the same chromosome that had more
than 95% homology were grouped together. 70-mer oli-
gonucleotides were designed for each open reading frame
of L. infantum and L. major with consistent thermody-
namic properties using automated bioinformatic proce-
dures. Probes were initially designed for L. infantum with
the added requirement that the region targeted by the
probe had optimal homology between both species. For
common probes, up to two mismatches were tolerated. In
the case that more than 2 mismatches were present in a
given gene between L. infantum and L. major, a new probe
was designed specifically for L. major (956 probes). The
microarray includes in total 8,978 70-mer probes that rec-
ognize with no mismatches all L. infantum genes (8,184,
GeneDB version 3.0) and also all L. major genes (8,370
genes, GeneDB version 5.1) with the majority of the
probes sharing no mismatches and a small percentage of
the probes having at most two mismatches (3,580
genome probes are 100% identical between L. infantum
and L. major and 3,410 probes have 1–2 mismatches).
Also, 622 control probes were included in the microarray
for assessing synthesis variability, location of the probe
within a given open reading frame and number of mis-
matches. The probes were synthesised in 384-well plates
by Invitrogen (Burlington, Canada). The microarrays were
printed on SuperChip (Erie Scientific) using a BioRobotics
MicroGrid (Genomic solutions Inc, Ann Arbor, MI). Each
probe was printed in duplicate. To assess the ubiquity and
specificity of the oligonucleotide probes, the DNA micro-
array was hybridized in triplicate with genomic DNA iso-
lated from either L. infantum or  L. major. Following
scanning, both genomic DNA preparations hybridized
more than 99% of the oligonucleotides on the array (data
not shown). All microarray data will be freely available on
the Geo NCBI database in the MIAME format [73]. The
series accession number for our manuscript is GSE10407.
Preparation of labeled cDNA and microarray 
hybridization
Probes for DNA microarray hybridizations were prepared
with 10 μg of total RNA for each condition. Purified cDNA
from either promastigotes or intracellular amastigotes wasBMC Genomics 2008, 9:255 http://www.biomedcentral.com/1471-2164/9/255
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dried in speed-vac and resuspended in 0.2 M sodium
bicarbonate buffer pH 9.3. Alexa 555 and Alexa 647 dye
(Invitrogen) was dissolved in DMSO and incubated in
dark with either cDNA for 2 h at room temperature. After
coupling, sodium acetate was added and cDNA was puri-
fied with MinElute PCR Purification columns (Qiagen)
and washed with phosphate washing buffer and phos-
phate elution buffer. The array was pre-hybridized with 5×
complete Denhardt, 30% deionized formamide, 6× SSPE,
0.5% SDS and 0.1 mg/ml ssDNA for 1 h at 42°C and then
washed twice for 5 min. at 42°C with 2× SSC, 0.1% SDS,
3 min. at 25°C with 1× SSC, 3 min. at 25°C with 0.2 ×
SSC and 3 min at 25°C with 0.05 × SSC. Hybridizations
were carried out overnight at 42°C (2.5× modified Den-
hardt, 30% deionized formamide, 6× SSPE, 0.5% SDS, 0.1
mg/ml ssDNA and 0.75 mg/ml yeast tRNA). Multiple bio-
logical replicates (4 for L. major and 6 for L. infantum) of
all hybridizations were performed to account for sample
heterogeneity, variation between slides and variations due
to hybridization. To prevent bias by preferential label
incorporation into particular sequences, Alexa 555 and
Alexa 647 dyes were swapped between the two RNA prep-
arations. Hybridized slides were washed using the pre-
hybridization buffer described above.
Fluorescence detection, data processing and statistical 
analysis
The fluorescence signal intensities of six slides hybridized
with  L. infantum RNA isolated from promastigotes or
amastigotes and four slides hybridized with the L. major
RNA (promastigote and amastigote) were measured using
the Perkin Elmer ScanArray Express Scanner. GenePix Pro
6.0 image analysis software (Axon Instruments, Union
City, California, United States) was employed to measure
the fluorescence signal intensities of the array features and
local background. Raw data from GenePix were imported
in R 2.2.1 for normalization and statistical analyses using
the LIMMA (version 2.7.3) package [74-76]. Before
processing, probes were flagged according to their hybrid-
ization quality on the Leishmania species [43]. Weights
were assigned to each array in order to give less weight to
arrays of lesser quality [77]. Data were corrected using
background subtraction based on convolution of normal
and exponential distributions [78]. Intra-array normaliza-
tion was carried out using the "print-tip loess" method
and inter-array normalization was done using the "quan-
tiles of A test" for each array [79]. Statistical analysis was
done using linear model fitting and standard errors were
moderated using a simple empirical Bayes [74]. Multiple
testing corrections were done using the False Discovery
Rate (FDR) method with a threshold p-value of 0.05. Only
genes statistically significant with an absolute log2 ratio
greater than 0.75 were considered as differentially
expressed. Further species comparison was performed
only on probes that had less than two mismatches when
hybridized to either Leishmania  species. Thus, 6990
probes could be directly compared between the two spe-
cies. Gene ontology annotation was analyzed using the
AmiGO website [80].
Quantitative Real-Time RT-PCR
Quantitative real-time PCR was carried out on a selected
number of genes for validating the microarray experi-
ments (see Table 5 and Additional file 5). Three independ-
ent RNA preparations (same used for the microarray
experiments) were conducted for each condition. First-
strand cDNA was synthesized from 2 μg of total RNA
using the Superscript III RNase H Reverse Transcriptase
enzyme and random hexamers (GE Healthcare) according
to manufacturer's instructions. The resulting cDNA sam-
ples were stored at -20°C until use. The primers were
designed using Primer Express 2.0 (Applied Biosystems)
and their sequence data are the following: × gene: 5-Ztail-
N-3; Y gene: 5-Ztail-N-3 (see Additional file 6). Equal
amounts of cDNA were run in triplicate and amplified in
a 15 μl reaction containing 7.5 μl of 2× universal PCR
master mix (Applied Biosystems, Foster City, CA), 10 nM
of Z-tailed forward primer, 100 nM of reverse primer, 250
nM of Amplifluor Uniprimer probe (Chemicon, Temec-
ula, California), and 1 μl of cDNA target. Reactions were
performed at the Gene Quantification Core Laboratory of
the Centre de Génomique de Québec using the Applied
Biosystems Prism 7900 Sequence Detector [81]. Three
technical and two biological replicates of each reaction
were performed, amplification efficiencies were validated
and gene expression levels were normalized to constitu-
tively expressed mRNAs encoding the ubiquitin hydrolase
gene (LinJ29_V3.2410/LmjF29.2300), 60S ribosomal
protein (LinJ18_V3.0630/LmjF18.0620) and a hypotheti-
cal protein (LinJ31_V3.0190/LmjF31.0180). Quantifica-
tion of the relative changes in target gene expression was
calculated according to a standard curve.
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